The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) discussed the safety reviews of a variety of medications during its June 2017 meeting. The medicines in review included treatments for
Drug Discovery
Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk. Animal studies
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research (NIHR) led by professors from the Universities of Liverpool and Bristol has discovered a drug
Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials. The
Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy. One
PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio
Last year, Cardiff, U.K.-based Verona secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic for work on its PDE3/PDE4 inhibitor RPL554, and has now teamed
Shire has secured label expansion approval from the European Commission for its hereditary angioedema therapy Cinryze. The European Commission (EC) has approved the label extension application, granting three new indications
Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in
Novartis has received FDA approval for Kisqali, a first-line treatment for breast cancer originally developed by the British biotech Astex Pharmaceuticals. The oncology company Astex Pharmaceuticals, located in Cambridge’s biotech hub, entered
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has
Actelion has received approval from the European Commission for Ledaga, a treatment to prevent the progression of a rare form of skin cancer. After being acquired by Johnson & Johnson
Diagnostics company, Owlstone Medical, who is developing a breathalyser for disease has announced it has signed a master service agreement with pharmaceutical company 4D Pharma. The agreement will see 4D
Sanofi and its vaccines global business unit Sanofi Pasteur announced today an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to develop and commercialize a monoclonal antibody–called MEDI8897–for the
A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of
Amarin, the Irish biotech that has developed a drug to help reduce very high blood fat levels, saw sales jump 59 per cent last year. However, the company still reported
29 – 31 March 2017, Glasgow, United Kingdom. DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting. The goal of the
GlaxoSmithKline plc and Innoviva, Inc. announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar Ellipta (fluticasone furoate/vilanterol,
Roche’s oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive
Lanthio Pharma has initiated a Phase I clinical trial with its lanthipeptide candidate MOR107, which is being developed as a
Researchers at Eindhoven University of Technology (TU/e) present a new method that should enable controlled drug delivery into the bloodstream
UK-based rare and speciality diseases group Mereo BioPharma says its brittle bone disease drug BPS-804 has been accepted to participate
Modus Therapeutics has raised €3.4M to support the completion of a Phase II trial for sickle cell disease, a painful condition
The University of Liverpool, in partnership with AKL Research and Development, will lead a clinical trial testing the potential of
Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google
A new biologic agent – the most potent of its kind so far – is showing early promise as part
Johnson & Johnson is counting on new buy Actelion’s pulmonary arterial hypertension (PAH) meds to provide a top-line boost once
The Irish Government risks losing out on hundreds of millions of euro in savings on its drug bill because of
The European Commission (EC) has granted marketing authorisation in Europe for Sanofi‘s Suliqua, a titratable fixed-ratio combination of basal insulin
As recently published in the International Journal of Cancer, researchers from Breast-Predict, may have found a new drug for the
Advertisements
